Abstract: Oral immunological tolerance is an essential although poorly understood phenomenon by which the immune system becomes """"""""non-responsive"""""""" against antigens administered via the intestinal mucosa. Although this process is vital for the co-existence with non-pathogenic intestinal antigens, such as food and normal microbial flora, the mechanisms responsible for oral tolerance remain poorly understood. Lymphocyte migration (homing) is essential for protective and pathological immune responses and we and others have demonstrated that gut-associated antigen-presenting dendritic cells instruct lymphocytes to express gut-specific homing receptors, integrin 4?7 and chemokine receptor CCR9, by a mechanism dependent on the vitamin A metabolite retinoic acid (RA). Importantly, RA also contributes to the generation of regulatory T lymphocytes (TREG), which have been shown to be important for the establishment of oral tolerance. Given that RA induces gut-homing lymphocytes and also promotes TREG differentiation, I hypothesize that RA is essential for the establishment of oral tolerance i) by inducing gut-tropism and """"""""sequestering"""""""" potentially pathogenic T lymphocytes in the intestinal mucosa and ii) by promoting TREG differentiation in the gut. If successful, my work will highlight a new physiological role of gut-homing in the establishment of oral tolerance, providing also a straightforward approach to induce immune tolerance using RA, which could be used in the treatment of autoimmune diseases. Public Health Relevance: My research could provide a straightforward approach to treat autoimmune diseases, such as multiple sclerosis, diabetes, psoriasis and rheumatoid arthritis. It would also offer a simple method for boosting intestinal immune responses for vaccination purposes, such as in infections by Salmonella, rotavirus, and HIV.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2OD006512-01
Application #
7852613
Study Section
Special Emphasis Panel (ZGM1-NDIA-O (02))
Program Officer
Basavappa, Ravi
Project Start
2009-09-30
Project End
2013-09-30
Budget Start
2009-09-30
Budget End
2013-09-30
Support Year
1
Fiscal Year
2009
Total Cost
$2,654,750
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Villablanca, Eduardo J; Cassani, Barbara; von Andrian, Ulrich H et al. (2011) Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 140:1776-84
Villablanca, Eduardo J; Wang, Sen; de Calisto, Jaime et al. (2011) MyD88 and retinoic acid signaling pathways interact to modulate gastrointestinal activities of dendritic cells. Gastroenterology 141:176-85
Wang, Sen; Villablanca, Eduardo J; De Calisto, Jaime et al. (2011) MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J Immunol 187:141-50
Cassani, Barbara; Villablanca, Eduardo J; Quintana, Francisco J et al. (2011) Gut-tropic T cells that express integrin ?4?7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology 141:2109-18